Cargando…

Sodium-glucose cotransporter 2 inhibition: which patient with chronic kidney disease should be treated in the future?

The advent of sodium-glucose cotransporter 2 (SGLT2) inhibitors represents a major advance for people with type 2 diabetes (T2DM) and chronic kidney disease (CKD). The results of the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial have cle...

Descripción completa

Detalles Bibliográficos
Autores principales:	Neuen, Brendon L, Jardine, Meg J, Perkovic, Vlado
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6993192/ https://www.ncbi.nlm.nih.gov/pubmed/32003833 http://dx.doi.org/10.1093/ndt/gfz252

Ejemplares similares

Sodium‐Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta‐Analysis
por: Arnott, Clare, et al.
Publicado: (2020)

Sodium‐glucose co‐transporter‐2 inhibitors with and without metformin: A meta‐analysis of cardiovascular, kidney and mortality outcomes
por: Neuen, Brendon L., et al.
Publicado: (2020)

Chronic kidney disease and the global NCDs agenda
por: Neuen, Brendon Lange, et al.
Publicado: (2017)

Findings of Sodium-Glucose Cotransporter-2 Inhibitor Kidney Outcome Trials Applied to a Canadian Chronic Kidney Disease Population: A Retrospective Cohort Study
por: Yi, Tae Won, et al.
Publicado: (2022)

Sodium-glucose cotransporter 2 inhibition: towards an indication to treat diabetic kidney disease
por: Górriz, Jose Luis, et al.
Publicado: (2020)

How should we monitor the cardiovascular benefit of sodium–glucose cotransporter 2 inhibition?
por: Tanaka, Atsushi, et al.
Publicado: (2020)

Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease: Results From the CREDENCE Trial and Meta-Analysis
por: Zhou, Zien, et al.
Publicado: (2021)

Sodium–glucose cotransporter inhibition in polycystic kidney disease: fact or fiction
por: Afsar, Baris, et al.
Publicado: (2022)

Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function: Data From the CANVAS Program
por: Neuen, Brendon L., et al.
Publicado: (2018)

Sodium-Glucose Cotransporter Inhibition Prevents Oxidative Stress in the Kidney of Diabetic Rats
por: Osorio, Horacio, et al.
Publicado: (2012)

Metabolomic profiling in kidney cells treated with a sodium glucose-cotransporter 2 inhibitor
por: Jo, Hyung Ah, et al.
Publicado: (2023)

Inhibition of Sodium Glucose Cotransporters Improves Cardiac Performance
por: García-Ropero, Álvaro, et al.
Publicado: (2019)

Effect of Sodium-Glucose Cotransport Inhibition on Polycystic Kidney Disease Progression in PCK Rats
por: Kapoor, Sarika, et al.
Publicado: (2015)

Renal glucose handling in diabetes and sodium glucose cotransporter 2 inhibition
por: Poudel, Resham Raj
Publicado: (2013)

Sodium‐glucose cotransporter 2 inhibitors in heart failure with chronic kidney disease
por: Kato, Shingo, et al.
Publicado: (2022)

Hyperkalemia and renin-angiotensin aldosterone system inhibitor therapy in chronic kidney disease: A general practice-based, observational study
por: Jun, Min, et al.
Publicado: (2019)

Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA(1c), disease duration and treatment intensity: results from the CANVAS Program
por: Young, Tamara K., et al.
Publicado: (2021)

Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes
por: List, James F., et al.
Publicado: (2009)

Energy Balance After Sodium–Glucose Cotransporter 2 Inhibition
por: Ferrannini, Giulia, et al.
Publicado: (2015)

Sodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A Review
por: Kalra, Sanjay, et al.
Publicado: (2016)

Sodium-glucose cotransporter-2 inhibitor use in kidney transplant recipients
por: Ramakrishnan, Pavithra, et al.
Publicado: (2023)

Renal Glucose Handling: Impact of chronic kidney disease and sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes
por: Ferrannini, Ele, et al.
Publicado: (2013)

The Application of Sodium-Glucose Cotransporter 2 Inhibitors to Chronic Kidney Disease Stage 4
por: Koguchi, Ayako, et al.
Publicado: (2017)

Editorial: The role of sodium-glucose cotransporter 2 inhibitors in the management of chronic kidney disease
por: Heerspink, Hiddo J L, et al.
Publicado: (2020)

Sodium-glucose cotransporter 2 inhibitor effects on cardiovascular outcomes in chronic kidney disease
por: Shivakumar, Oshini, et al.
Publicado: (2020)

Sodium-Glucose Cotransporter Inhibitors as Antidiabetic Drugs: Current Development and Future Perspectives
por: Maccari, Rosanna, et al.
Publicado: (2022)

Role of sodium/glucose cotransporter inhibition on a rat model of angiotensin II–dependent kidney damage
por: Reyes-Pardo, Humberto, et al.
Publicado: (2019)

Mapping the metabolic reprogramming induced by sodium-glucose cotransporter 2 inhibition
por: Kogot-Levin, Aviram, et al.
Publicado: (2023)

Roles of Sodium-Glucose Cotransporter 2 of Mesangial Cells in Diabetic Kidney Disease
por: Wakisaka, Masanori, et al.
Publicado: (2021)

Sodium-Glucose Linked Cotransporter-2 Inhibition Does Not Attenuate Disease Progression in the Rat Remnant Kidney Model of Chronic Kidney Disease
por: Zhang, Yanling, et al.
Publicado: (2016)

Pleiotropic Effects of Sodium-Glucose Cotransporter-2 Inhibitors in Cardiovascular Disease and Chronic Kidney Disease
por: Rastogi, Anjay, et al.
Publicado: (2023)

Erratum. Sodium–Glucose Cotransporter 2 Inhibition and Diabetic Kidney Disease. Diabetes 2019;68:248–257
por: Alicic, Radica Z., et al.
Publicado: (2019)

Role of sodium-glucose cotransporter 2 inhibition to mitigate diabetic kidney disease risk in type 1 diabetes
por: van Raalte, Daniël H, et al.
Publicado: (2020)

Sodium-glucose cotransporter 2 (SGLT-2) inhibition and kidney protection: Does improvement in kidney hypoxia play a role?
por: Burnier, Michel
Publicado: (2021)

A Novel Risk Prediction Model for Severe Acute Kidney Injury in Intensive Care Unit Patients Receiving Fluid Resuscitation
por: Feng, Yunlin, et al.
Publicado: (2022)

Sodium-glucose cotransporter-2 inhibition and the insulin: Glucagon ratio: Unexplored dimensions
por: Kalra, Sanjay, et al.
Publicado: (2015)

Sodium-glucose cotransporter 2 inhibition and health benefits: The Robin Hood effect
por: Kalra, Sanjay, et al.
Publicado: (2016)

The effect of sodium/glucose cotransporter 2 (SGLT2) inhibition on the urinary proteome
por: Cherney, David, et al.
Publicado: (2017)

Sodium-glucose cotransporter 2 inhibition prevents renal fibrosis in cyclosporine nephropathy
por: Castoldi, Giovanna, et al.
Publicado: (2021)

Sodium-Glucose Cotransporter-2 Inhibition Benefits in Cardiorenal Risk in Men and Women
por: Pruett, Jacob E, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_r2ifa3g00o1u4sbj3qfd853hau